Celcuity launches REVTORPYK for HR-positive, HER2-negative advanced breast cancer
Celcuity Inc is launching REVTORPYK for HR-positive, HER2-negative advanced breast cancer, with broad clinical development in breast and prostate cancer. Expanded manufacturing is planned, alongside subcutaneous formulation and new indications.
REVTORPYK is launching for HR-positive, HER2-negative advanced breast cancer, with broader clinical development in breast and prostate cancer also under way. Market access efforts are robust, and expanded manufacturing is planned. A subcutaneous formulation and new indications remain in development.